| Drug Type Tetraspecific antibody | 
| Synonyms Therapeutics LASER (OPKO) | 
| Target | 
| Action modulators | 
| Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD20 modulators(B-lymphocyte antigen CD20 modulators), CD28 modulators(T-cell-specific surface glycoprotein CD28 modulators) + [1] | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| B-Cell Lymphoma | Preclinical | United States  | 09 Mar 2023 | |
| Leukemia | Preclinical | United States  | 09 Mar 2023 | 






